-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UZ/rwb9L7gDR50ksNihIMJybRn0BRl/opXP+o812ilHSM5YWX/3BLjOB1v4ixWJ1
 dEF4t/B/XIddMLlgan5+jA==

<SEC-DOCUMENT>0000950123-08-001498.txt : 20080212
<SEC-HEADER>0000950123-08-001498.hdr.sgml : 20080212
<ACCEPTANCE-DATETIME>20080212154133
ACCESSION NUMBER:		0000950123-08-001498
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20080211
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080212
DATE AS OF CHANGE:		20080212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELECTRO OPTICAL SCIENCES INC /NY
		CENTRAL INDEX KEY:			0001051514
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133986004

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51481
		FILM NUMBER:		08598303

	BUSINESS ADDRESS:	
		STREET 1:		3 WEST MAIN STREET, SUITE 201
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
		BUSINESS PHONE:		914-591-3783

	MAIL ADDRESS:	
		STREET 1:		3 WEST MAIN STREET, SUITE 201
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y48668e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>








<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>
Date of Report (Date of earliest event reported) February&nbsp;11, 2008</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Electro-Optical Sciences, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">
(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other jurisdiction <BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-51481</B><BR>
(Commission<BR>
File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>13-3986004</B><BR>
(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>3 West Main Street, Suite&nbsp;201, <BR>
Irvington, New York</B><BR>
(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>10533</B><BR>
(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
Registrant&#146;s telephone number, including area code <B>(914)&nbsp;591-3783</B><BR>

(Former name or former address, if changed since last report.)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>

<TR>
    <TD><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</TD>
</TR>
</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>&#151; Entry into a Material Definitive Agreement</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tina Cheng-Avery has been appointed to the position of Vice President of Commercialization of the
Registrant, effective as of February&nbsp;11, 2008.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Registrant has employed Ms.&nbsp;Cheng-Avery pursuant to an employment offer letter (the &#147;Offer
Letter&#148;) which provides, among other things, that Ms.&nbsp;Cheng-Avery will be an &#147;at-will&#148; employee.
Ms.&nbsp;Cheng-Avery will be paid an annual base salary of $200,000. In addition, Ms.&nbsp;Cheng-Avery will
be eligible for a discretionary bonus equal to 25% of her annual base salary upon the attainment of
certain to be determined goals. The Registrant has also agreed to grant Ms.&nbsp;Cheng-Avery an option
pursuant to the Registrant&#146;s 2005 Stock Incentive Plan to purchase up to 80,000 shares of the
Registrant&#146;s Common Stock at an exercise price per share equal to the closing price of the
Registrant&#146;s Common Stock on the date of the meeting of the Registrant&#146;s board of directors at
which such grant is approved. The option will vest in part based on time and in part based on the
attainment of milestones, as more specifically set forth in the Offer Letter.</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0px; text-indent: 0px"><B>Item&nbsp;5.02</B> <B>&#151; Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.</B></div>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As discussed above in Item&nbsp;1.01, Tina Cheng-Avery has been appointed to the position of Vice
President of Commercialization, effective as of February&nbsp;11, 2008.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ms.&nbsp;Cheng-Avery joins the Registrant from Pierre Fabre Dermo-Cosm&#232;tique USA/Genesis Pharmaceutical
where she served since 2007 as Vice President of Marketing of this division of Pierre Fabre Group,
an independent French pharmaceutical company. From 2005 to 2007, Ms.&nbsp;Cheng-Avery was Global
Marketing Director for Skin Care for Elizabeth Arden, Inc., a global prestige beauty products
company. From 2001 to 2004, she served as Vice President of Marketing of Wella Personal Care of
North America, Inc., the North American subsidiary of Wella AG, a global prestige beauty product
company controlled by The Proctor &#038; Gamble Company since 2003. Prior to this, Ms.&nbsp;Cheng-Avery held
various marketing and financial positions at different public companies. Ms.&nbsp;Cheng-Avery holds a
Master of Business Administration degree from the J.L. Kellogg School of Management at Northwestern
University and Bachelor of Business Administration from the University of Michigan. Ms.
Cheng-Avery is 44&nbsp;years old.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On February&nbsp;12, 2008 the Registrant issued a press release announcing the appointment of Ms.
Cheng-Avery as the Registrant&#146;s new Vice President of Commercialization. A copy of the press
release is furnished as Exhibit&nbsp;99.1 to this report. Exhibit&nbsp;99.1 is furnished to, but not filed
with, the Securities and Exchange Commission. Registration statements or other documents filed with
the Securities and Exchange Commission shall not incorporate this information by reference, except
as otherwise expressly stated in such filing.</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>&#151; Financial Statements and Exhibits</B></TD>
</TR>
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(b)&nbsp;Exhibits<I>.</I></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Offer Letter, dated January&nbsp;16, 2008, between the Registrant and Tina Cheng-Avery</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of the Registrant dated February&nbsp;12, 2008 titled &#147;Electro-Optical Sciences
Expands Management Team&#148;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Electro-Optical Sciences, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: February 12, 2008&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Richard I. Steinhart
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">(Principal Financial Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT INDEX
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>EXHIBIT</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>NO.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>DESCRIPTION</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Employment Offer Letter, dated January&nbsp;16, 2008, between the Registrant and Tina Cheng-Avery</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release of the Registrant dated February&nbsp;12, 2008 titled &#147;Electro-Optical Sciences
Expands Management Team&#148;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>y48668exv10w1.htm
<DESCRIPTION>EX-10.1: EMPLOYMENT OFFER LETTER
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">January&nbsp;16, 2008
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tina Cheng-Avery<BR>
575 Hillside Street<BR>
Ridgefield, NJ 07657

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dear Tina:</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">It gives me great pleasure to offer you the position of Vice President of Commercialization,
Electro-Optical Sciences, Inc. This is a critical post as EOS prepares for the commercialization
of MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting to the President &#038; Chief Executive Officer, and working closely with the Operations,
Software, and Clinical Trials Departments, you will be responsible for the following: (1)
development and final commercialization strategy, this is to include professional sales and
marketing, consumer marketing and re-imbursement; (2)&nbsp;managing all sales and marketing staff,
outside consultants and agencies; (3)&nbsp;working with the CEO on business development activities with
respect to commercialization partners; (4)&nbsp;devising and implementing tactical plans for successful
launch and commercialization of MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> and all other Company products (5)&nbsp;fostering
and maintaining contacts with influential thought leaders in dermatology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation will consist of a yearly salary of $200,000 paid semi-monthly ($8,333.33) and a
grant of options to acquire up to 80,000 shares of EOS common stock according to the company&#146;s
Employee Incentive Stock Option Plan. The options are exercisable at a value equivalent to the end
of day trading price of MELA stock on the date of issue (this is the date approved by the
Compensation Committee of the Board of Directors) and will vest according to the following
schedule: (1)&nbsp;25,000 options vesting; 12,500 options on the day of hire and the balance vesting in
equal portions over the next four years, yearly on the anniversary of the date of hire; (2)&nbsp;25,000
options upon completion of the first product launch/first commercial sale of MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>;
(3)&nbsp;and 30,000 options based upon profitability of EOS. Acceleration of option vesting will be
triggered by the occurrence of an Acquisition Event (as defined in the Plan); provided, that any
Acquisition Event that results in EOS&#146; Board of Directors consisting of individuals who are the
same as, or share affiliations with, the directors representing at least 51% of the Board of
Directors prior to the Acquisition Event, shall not be considered an Acquisition Event for the
purpose of this paragraph.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The position requires significant travel, particularly during the initial phase of
commercialization. Thereafter, travel is not anticipated to exceed 50% per month, on average.
Reasonable travel expenses and other business expenses will be reimbursed upon submission of
receipts in accordance with EOS&#146; business expense
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reimbursement policy. You will be provided a cellular phone with remote e-mail capability for
EOS business use, exclusively.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a development stage company with no earnings, EOS is not in a position to offer a yearly
cash bonus. However, we have agreed to provide you with a 25% discretionary bonus based upon
attainment of goals to be agreed upon. You will be issued a corporate AMEX credit card, to be
used for EOS business, and reasonable expenses charged to that card will be paid upon submission of
appropriate receipts. As you know, employment in the state of New York is on an &#147;at will basis,&#148;
meaning either you or EOS may terminate your employment at any time with or without cause. In
addition, this offer is contingent upon a successful background check.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You will be eligible to participate in EOS&#146;s health insurance plan, which includes family
medical, and prescription drug coverage, as well as a non-contributory Simple IRA. You will be
granted 4&nbsp;weeks of paid personal time off (PTO).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The start date for full-time employment is February&nbsp;11, 2008. The position is based full-time
at EOS headquarters, presently at 3 West Main Street, Irvington, NY. Although occasional
telecommuting is permitted with prior approval of the President &#038; CEO, this position requires
maximal time on premises or at clinical trial sites and customers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is an exciting time for EOS. The future of the company depends on our ability to
efficiently execute and achieve the milestones that we have set. I believe that you can make a
great contribution in helping to achieve our goals. Moreover, I feel that you will be able to work
effectively with our fine staff, and enhance the professionalism of EOS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please sign below indicating your acceptance of the offer and mail it to me at my office.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please call me if you have any questions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%">Sincerely,

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 50%"><font style="border-bottom:1px solid #000000">/s/
Richard I. Steinhart&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><BR>
Richard I. Steinhart<BR>
Vice President &#038; CFO

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">ACCEPTED AND AGREED:
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD style="border-bottom:1px solid #000000" colspan="1" valign="top" align="left" nowrap>/s/ Tina Cheng-Avery&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Tina Cheng-Avery</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">Date:  February 11,2008
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>
</table>
</div>




<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">3 West Main Street Suite&nbsp;201, Irvington-on-Hudson, New York 10533<BR>
 (Tel) 914.591.3783 x10; (Fax) 914.591.3785<BR>
jvgulfo@eosciences.com

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>y48668exv99w1.htm
<DESCRIPTION>EX-99.1: PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="y48668y4866800.gif" alt="(ELECTRO-OPTICAL SCIENCES, INC. LOGO)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>For Immediate Release</B><BR>
<U>For further information contact</U>:<BR>
David Carey<BR>
Lazar Partners Ltd.<BR>
(646)&nbsp;239-6231<BR>
dcarey@lazarpartners.com

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Electro-Optical Sciences Expands Management Team</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IRVINGTON, NY, Feb 12, 2008 &#151; Electro-Optical Sciences, Inc. (&#147;EOS&#148;) (NASDAQ: MELA), a medical
device company focused on the design and development of MelaFind<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>, a non-invasive,
point-of-care instrument to assist in the early diagnosis of melanoma, today announced the
appointment of Tina Cheng-Avery to the Company&#146;s senior management team.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Tina comes to us with over 20&nbsp;years of experience in the commercialization of dermatology products
from Aveeno, Neutrogena, Elizabeth Arden, and Pierre Fabre. Her insights into consumer behavior,
the workings of the dermatologist&#146;s office, and market preparation will be invaluable to us as we
continue pre-commercialization efforts and discussions with potential partners for the
commercialization of MelaFind,&#148; said Joseph V. Gulfo, MD, MBA, President and CEO of Electro-Optical
Sciences.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;I am thrilled to be joining EOS and working on MelaFind. It is an important product that I am
confident will resonate with both patients and caregivers in the dermatology field,&#148; said Tina
Cheng-Avery, Vice President of Commercialization. &#147;In my experience in dermatology, the two things
that matter most for a new product are patient demand and practice dynamics, both of which, I
believe, are very favorable for MelaFind.&#148;</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ms.&nbsp;Cheng-Avery joins EOS in the newly created position of Vice President of Commercialization from
Pierre Fabre Dermo-Cosmetique USA/Genesis Pharmaceutical where she served as Vice President of
Marketing and managed the Avene and Glytone dermo-cosmetic skincare product lines distributed
through dermatologist and plastic surgeon offices.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Previously, Ms.&nbsp;Cheng-Avery was Global Marketing Director for Skin Care at Elizabeth Arden, Inc.
where she managed a $300&nbsp;million skin care portfolio. In addition, she led a collaboration between
Elizabeth Arden and Allergen Pharmaceuticals and was responsible for launching Prevage Anti-Aging
Treatment.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Other key positions she has held include Vice President of Marketing for Wella Personal Care of
North America, group product director at Johnson &#038; Johnson&#146;s Neutrogena Corporation, and Associate
Brand Manager for Aveeno at S.C. Johnson &#038; Family, Inc.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Ms.&nbsp;Cheng-Avery holds a Master of Business Administration degree from Northwestern University.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">About Electro-Optical Sciences</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">EOS is a medical device company focused on designing and developing a non-invasive, point-of-care
instrument to assist in the early diagnosis of melanoma. MelaFind features a hand-held imaging
device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. Using sophisticated algorithms, the data are then analyzed
against a proprietary database of melanomas and benign lesions in order to provide information to
the physician and produce a recommendation of whether the lesion should be biopsied.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Melanoma is the deadliest of skin cancers, responsible for approximately 80% of all skin cancer
deaths. Unless melanoma is detected early and excised with proper margins, the patient survival
rate is poor, as there is currently no cure for advanced stage melanoma.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For more information on EOS, visit www.eosciences.com.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Safe Harbor</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release includes &#147;forward-looking statements&#148; within the meaning of the Securities
Litigation Reform Act of 1995. These statements include but are not limited to our plans,
objectives, expectations and intentions and other statements that contain words such as &#147;expects,&#148;
&#147;contemplates,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;intends,&#148; &#147;believes&#148; and variations of such words or
similar expressions that predict or indicate future events or trends, or that do not relate to
historical matters. These statements are based on our current beliefs or expectations and are
inherently subject to significant uncertainties and changes in circumstances, many of which are
beyond our control. There can be no assurance that our beliefs or expectations will be achieved.
Actual results may differ materially from our beliefs or expectations due to economic, business,
competitive, market and regulatory factors.</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"># # #
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>y48668y4866800.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y48668y4866800.gif
M1TE&.#EAF@!+`.8``&QNDV>APZ?&VN?H[.OR]+?0X>7M\<[<Z?[^_M3BZY:Z
MTV6=PO[^^V69PO#S]62;OHBRS;#,W<C(U-'>ZH>)J&B=PK:WQ_CY^FF=Q,K;
MY]GE[,W?Z*6EN_7Y^6F:Q/S\_/'V^'"CQ(.MS/_^^I>9LF*9PL'9Y/SY^F:=
MQ-K:XGVKRT-'=OWZ_&B:PIO`U-34W).6K8VUT&::Q-'<YOK\^?S^_/[\_=_K
M[[G5X-WG[[_4X_S\^E98@_K\_/S^^L[1UOC[^WNKQ<+$T/[\^O/X^/S^_F:?
MOF.>PG.CQ_[]_79YFWJFRGV`F:'!V&V?Q*BKON#BYOW^^,7<YOO\^/G\]W^#
MHF&9O/CW^&)EC)ZAL["SP\_BZ72GQ'>IR9*[T82'H8R/J'FEQN[N\?S^^+^_
MR];7X=;G[;W!T7&@Q>SO[LS8Y62;PVJ?P_S]_?;U]\W-V&&4POW]^H&PRFJ?
MQWY^HJZOOM_?Y;J]SFN9Q<;7YIV=MI&1KEZ1P+_0X66@Q?___R'Y!```````
M+`````":`$L```?_@'^"@X2%AH>(B0@(A`A)B9"-D$F,B)64D9E_F)J=GHIQ
M236C0W\UC`PC?PP(-::N8S8C<3N?AHLC.ZU_"!^C##8,@L*"-G%_M0@GP969
M-JZ]'\$L22/$@Q^#-=>JFX^VF@AQ-D6^-JN5/1UN(.UN%ZTV"`P^U^""O6UC
M?R,L.ZQ_/@"Y<`4(D"2B1@RAM8,2"P2U(GTXL:J--%9)6'1P8,#,`1,F=$C9
M<H-`AT<C,MJ0=T\3@Y<(1IQPH"%#`0%-7"B($4-!$QUF.L0<UW+02V(?B!A(
MH","SB9-!`B(@$,#`1J.&+1QM"@3`BHL1LQC<<'`A@@N(*CH@@1/`#0A_[BH
M$.&B0(X.#.(L:E84$8,/(&[@$!!##I<03MA@:+&F!08V(52XP&'@PK>628;L
MZ$!@1@0%:A&SJ6#$"!LG`4($@2`@3^4V6[M%:E,CU`4".II`Z!*BPIH2,AHL
M>.!A08D&#3"$$-%$@]"^@_9*1]"#@)0F(D($D+$&.?(6+0)@0('<0X7E$0QL
MY>7U&@(@!#((@("$S8(%1V0LD%&AP9$6P?TG`QM(0!!!#D0LP@I?^#"BX`4:
M%!!#"$8`*$,+%52`@GA^M+!``!6TX,<:,F`@0@0$',/>/6+5D,0%,M$`P@8Q
M8%!""6Z1-AX;:P3@`8@;EN#C'#?&D`,0(UP`R?]+.QPS`GQ2Q-""%3AZ*)X,
M)7B`QV-L7#F'!QCX<2,7*$[4"D"#)#$%`RQ,`4(!(5#9@GT!^*&A<#W^^$`%
M"U3`QH]85N""`:J<8(\GC"B41!P@2.&%$50^\(`1#000P(<M'.%'`'B`9X0'
M,LB`PI\E0*#!"++=LM4'20!F`@1&'.='`T;XT6>(FZYQQ!HA=MD`&UNRT4`)
M*!C9@S4K$>+#!P)IX,6-CF'@084/V+G`&GYX(&1W#X19@0=S8%":`!<PX,H]
MXL3!P`4;>.%$?N+QB5P%3J`1A@ISJ7"8'S+@D:&T&&#I!0B'$L+`(SL84``$
M*)!88@#(&8&!$UV(``'_3VJAP08*1V#@UF,M"&=$&#J4>XK!-C@000A''('"
MG"C(<(032,C1TTXB+!'"<"6&B\(<?:Z!1@);769+*&_*842/,HBGJVI>N#!5
M`07T40!:(CC16)\>O+P&%P;\4<0A"/CP!Q%;N(!&`RAD&`#');`1A!=-1%"`
M#GGDH<--"JC0-1YM8Q!B>"6HD`,O]C#000%(Q'U$B$NC(8("=IN@1@9YX("U
M$SV/-P>(6)K0`T*>I/('"W_$8<#*+5<0,`H/H!&#``5<OL$$&]R^P0$;]*$`
M&W/TN"5C%9S:C+G`[)!P`7(L@%P`+73]@!,0-%%`'KSC/L,!O&]ADP)KCQKF
M_\\8N"R`4&8;\T<'4G!1@L=='[&`'$W@($7NW'._!?<Z""`"&R)R3-O6P(8-
M?(!!2VK2%&SP@1RXP`F5X@\&*L6:/.`N?[>;P!8F<(`93"`/(IA#B03'IQ9L
MP#TU\,$)3@"$&R@@!`TH$8:<5P$5"$`'^./>!!*@`0WP$'<;R(,`5$`<%&QH
M#B$*@`AN,(H1V"`*'TB`'$@TJCDT(`1>T,$!O)?!'IK!AQS<P,(J,"L/\*L"
M<M!`-CPQ@@/V``$)$,$#%N`!+>%!!B$00`:VL`$U3"`'`R!`.XC@A@Z`@``W
MT$`3OO2V.?CA"&R0`B%60H,D`,$$77#9M`A7`C3H$?]W:IA!`DH"`H/T0!V'
MO$$"/A(&;"D&7#T*P0%ZP0C5Q8!6T>L1$@2P@1F$,@<$<`,0F,6LZBQE`HZR
M40!*X`0%Z"`!;N"$)MK@@Q'<(`A6V!`>V``I,LU@`U(XP`U`8!GIJ&(12>B`
M`(0%KO&4@`M;:,0B>F`"#%AA#B@P0K4(&(,";%`-&[!*.0$"DY?<Q@X3:$*=
M/$"G3J%!!Q]H@TPZH(,'\`I8;W-!_G+@@"LH2!CK04`;`I.`/"@@9')HS0$T
M,+IS=,(&[%I"J(RX`#^P`0(Z^.8H0;"5KKB'&JP0@!$R-"`^Q4`#;4`3`@@@
M`!C645RSVF4&='H#!_1`'B__.5T2,))"5EQ`##K`I@R^]#/Q1(`(-3A!$@B@
M`"M<R'4V+<`."=`#F"0A69MH0^ILL`,":.``$8@`]N:Z*`068B]_,4,7LE3'
M2A6K#WS4@!@^T`V13C(*=_T#"$30MA*Q`8\"R($JVK!5!ZQS#69$0==0L(0(
M</"/!(`1`A["EUZ@#A>"R$$,NJ68/R4G`B`XW10,``$K.&9`S"R`!ARPU7I,
M@1K?>,@P!`&"'/22>PDP0`WZ85BC:*4&;7!A"3Z$@0#D1P1]R%T.0&`#:1;B
M!%181!31X(>8;6P!,=#!#50Q!!L0H0!H*(';Q-,"%?CS`!,P@%!<BB@"-.%7
M&/#<__2`RX\1Y&"*^M'0?@20AH8P:P@(6`F##P$"#7BPJCWH!)N"X4(4N&4!
MY96!"'0P@0D,0$DK,>Q+VF`#']S`!8Z!L0?6$(0(',`!V_@`19&PA@6T0)_%
M,7`'EYOB>]3`P;32D+3\$(("!%<>-Q#!&J1EQ(V)P`0$`_$0VA@)!E[!`:7\
M1"^&`((FL.$!&PO1&L)0``0;`'6I,D0-PL*"'[]+/%;,XTI/@(`I=&`#*FC`
M`UK@+^04>0(9N`$1CE&P3AA``0WP0X0_2V0I!'<(;6`K<`#H@1:@8`%!""T(
M'-3=002#%YGI]"%&,(4H4-0)"Y!8MJ[8!-Z]Y@_U:"_9&/^8`'>M84-A8H,+
M,I!@L\5!MT+:CA^,<(0EZ'$#-W!#3+`!#@VHX*(ML*(,O+`%!YR#"B"(`'+"
M-8<'!&`-IF&.":PR3'\@4!BHYL4!NT((L7Q@!S4H`@L^0(4HRJ$!/\(#KXS@
MA3R`&QX9F<<!_R#150BBA1%8@A'Z=*E*N2`/,]"`&_3J!@',<4/AJ5830GF#
M"XQX$R]-`@U&8`)A#574CPLM$<X)A`W`,%?BD5:F"*0""$A-*@4P@1D(@%9^
M!"0F0V"%L@<AEG[XP`=3H$X4;@`!.&Q(FPV`@,5S4-</1($&P\"L16YC!@D]
MX#A&)-PN<6>&E8LE`QZ:(&/N+8+_#(`;*RWY2TP0$(/C2(Q'1,Z``8#@\52[
MH%]NP8.H1=V8[=R(2C?B@Q4BTP0I$``(<:`(`X;`@G-%A]$]4-=>0""`;#YF
M@G/H,@^)8)`+7*`#1$@E[CXC`AN5H$<8,F(%T!"!!'APUDEU0^-%):YJA2`"
M6]!`<!D-CA'4H`<GL";G*@#)!W3,!0EP-\<9<8$#0$!X/L*`%<-EIS^1AT<0
M^\UQ5)">-W[@(8'F=C)B`#F0``E0=TB`9^+Q)U:@`E!!.X$E%4W@!87!!<M$
M)6N@*V147R_33,\D2@2@&0^A`U907GZ0+0'`!DTP`<NU<4;C"7$0!R-`!`H@
M8!KB)VNP_P1Y<!>"@`D?8``X(`<5`#VBIACR]QBH-1[XT6JC01Z_H0(Z,&LU
M8`.ET`@$8`)IH0)H@`2(D2%TA$\0PR=.UF0-8`7(<2.2AG<`@R'(<01HP!K4
M=@`<Y0,[<`)TI@+O,X0O<P0B(`430``?@!2=$&+GP@*:H0/;44+EPP:NI1Z"
M<$"L0`0YD!LJ("U4I%IO$X9>B`+;]BTS5`(M,"C,PB!`$`%(@!P9*!P"!##D
M(P,CHEH=XQC1$RKFI7PBTAT-X`0B(``FD$$W(!364`,?8`)F!R;C@6<K:`;#
MM$:(\@R"0$W7Q#9^LACX=0`)$%R&\`$.D``VH1M!@`8!@R<5,/]'31A_$19A
M%6!%%2``#N`+A4``2\`'T0,F;@$F*``R?K`E#,4?YG&/Y.>*1L0QY"$I&%`@
MUG,[UOB+8S,(%Z``<+`=9/8`*M`'"4``><$2S7@N-4![#X`'^(2#2U``X)8-
MI$,(/[A*&V`"3J$`<J`"2.`$X]%D(P0FX2(X<X!/#2`'";!QA&`&P_(8;?,G
M\1<`X5*/]65>`')\PZ*4)6`%IE$Q"G!#U)8[,W`7E,`-.:!Y#/48#"4`9:!=
MJK!U@X@)BE,`1,B55R0`6Z0DO,`@!U-=?>1!!X`Y>[.2$(`&X<$ICS$@`3,'
M+=!EE%<(!N`$<:,ABN$S6W*/0S8L5B#_*4+B!)&Q&C'@!0H0E9730=_41_P6
M$P_Q?PPP!3HP9$V(`3GX3/!`:^`@4A\@!4M`1]DB+&R@`!8G!DDP-@5S3IQQ
M3$"T.]R#.1$0!$RC&*KU)P0T!Q%`!8=2BEV`!O6B-9_%4&""1SP1-0]H-SH`
M$I=C>'N$8+NS`3Q4$J<9%HC%`&PEFOVX;I+7"JB`*.;2!AH15@T`'B"2+3%@
M`B1A`RRP((>"$##Q`5=P2`;@0PF@0;TT`07`!>EVCQ%6?W]9`.7"%TEP`S<!
M%5[@(P"4+0$C!_F#8-NC0[R3.QEP`&JP2AND`25!!#W5((401V;D:HS!!@)P
MC2\8#ENQ)H\6_P0/\"MK`#A^,)'>.6NU1G`-X@@7$'P$@$@YH`$;,$7R)P/@
MPH\%9@)L20A),``UMD,"\"5?\A@-L`8NL)L(66,#^D4:D`,Y8``&D`:"=`$\
MZ0B6H`,:XP$0US5=0!D]@#J?8"Y)X)Y$D`&1-AYZ$@#\IT&`6&N)`%*)\HA7
MH`%+T`#A<E_1XP</H`#7**0<1P0WX$$;X`)!>8X$)``]9*8W8`!B($@@P'L&
MP2QZ91199PV9=0CJ!$#;844-(`)Y``*4)6>,L&8$@`-<X%8E8D8E(`(BN04&
M$'ZKFJ>K(`^(U0,X\"=^<)/_,B!HH%Q$@)'XP`)`X``$8``ND"?GR/],[-@!
MI[0#/H"MD\0@-N">"X(((%"#@"HL:3<!%S`$"SF(ZE(#-]`$(3!><S)!A8-#
MQFISIJ.KIH"?BU`#C]8%R6%&#+4Q<=,$)/&@C7`.O=`!33!"(U0"UW<%R0H)
MZ(H/%MM=;`5CPB(XI9(#@:AKV7H,!U0$",`N-2(SXB$>:2=7&W`7A@H)(M4*
M+"`+(^``.B`'H)ATJB5QH;A'!$`)M8:Q.PJMI#D'!6`#508=B4``7D!'T/,M
M#1`#-R`*D0`,+-`&AE(#0BMFPI$A?%(!9S8!53EK12%2-9H7!!`!7=`GE>*)
M7`L!O9@#4YH('>`"0Q)CN5@`@6:UA@`"+O#_(03D:A4``0:@(HKPLU_Q)%L0
M`[AR(7C@`7OB`B8P`6I0&7'@>JFY$(M`!$/[:@'C(P1D?BU0GSN$C9$0N$("
M+@L@+`$0`5:'N(@`!.OD!U:P37*Z1#%!$9K@8`_`![##(:'"!0(P`]^4`TG5
M#S-:.B/0`9=K!6:X,3Z2@N2'`B<W`UM```A@FY!P`0*P`)LK:HYT!$T@3[Q;
M")BD)1!37FBP`2DF%O@0'?@`!&)0`$%`+-("/;L2`$&`0[MC`%3P!_C)LK/!
M&3@``15P?!"C&#XR+3*`!DU@>`<@!AWG%3H`0-\R*K:R!`1C+@@;OX.@`1#0
M`%L2,.73!"`0!ZS7_RI3$(@,/%);,$22-FFBPB,5L`2EQSU6L9ZWH!>MX`/S
ML`V/((R!H0,N0$3C]2./`T#D<01(H``B:8UA<[B)L`4A8%_FH2$>(`6Z0!MB
M&;^TMZ.(-F1<8`8T<`+2P`(T/`(]8`!;$`%R$`#!:U[9,AS4$P'X8Q7,>`@9
MP23KD3HLH!0)$`$QL#:,=8X#`BJ2YFWAA&!ID`T[.PSDR5D^4T(RT`4W\`=#
MP),JS`H)X`1X<+MAHBU>&P7G8$D$`%AR@`0A8R>V`B+WD5(6YYV5L;-Q@#IY
MP0A]9090+`)(X%:2VC4^DBVB,BD.F%Z[LUXJLLG8X')U])&N5BH&P``[</^O
M*JQ9M_0G7,HV7D``5(#'CKP$$-1DKC,:(_(`2^"YW5F1!_0!DDLVW_`!!)``
M!>`"R(PAD[)-1N"DC'0$)6`$05`7W)D``_`<_?"QBC`/1O<K8^PZ(J(`SI'(
MM,2TJ]H,7?'1IW`H11`'8)R$TF)O3C`[NZ$U`60?_3$K&+#0M;,_$Q!N2947
M614=B]`&%^`&!&`&)D`8*@"3SV9$MF($/R-`_,$&0MP'U(8[596?Z^=>B@"S
M;%4MQC@@'HE&!3!Y.1T**[2NPB">;'(,"3L*:\(/>]$&<4`$$0`F1LA0`"*O
M`](T6^+,05P7:J!#_%8-](`5.0T;5T!W-Q$#81#_`CQB'N%QCT?P(P*T'P\0
M`JRA151YIHBGHI\@$PF@`IRXE?GX(UDBQ%)PHN0J>[26VH@5!ST`!!U@2-UJ
M!EO0!R[P(S^SV'X)<1J"U_5+V;Q48T3<86+1TZT-VSFP!2;0!(BM+3=R'%\B
M:I<",>"!!\B!`B%`/UI48QNP!5/WP7V!*BH3!@O@2.G8HD:T!E9`,3%@/5)@
M!J-J`-UZI/&-IFAZ`V:0!WT@%0H@`D$0`L`+'%SY)QL#0!YC)\_]A@(P$N++
MQ>W`K=VJ2E)0`!,H!UW`!HV)AAT2/1GRW#^2@?$L.2X0`88'1')H$M4@%M6+
M*!"A`1&@`A4P(*/2,,+)_R\W`@=C%A?W@B\B(`)R(`+XH@)AP`6'<6=E^!LD
MDAR58A[R%S-?PBL1IEI(5)!-=S&4"14Y$0,0X.-AX`1RVMS<@2T!E"E*[3K1
MF80A$`9.5P#WLT';;08&``*H@Q#E^ZHMH2#;*"$;(Z><*,+1^>(-TX8ED!]K
M``?[48;>(2JBPC$D]#(3M!W7(I,!Z:0_PE`=8QPW@@*!?AR_@=#&(>@CO#$1
MUB]T%#,O?N3*T711B0-]O3];Y-!4=QGM9<V>``1XK`,*P`43+"X`Y!BCD2'F
MH>1L,Q[GZ&HQ,QZ6TH]+^.+.,R(8@`8J$`,JP`9'D+;_HGP!TRLQ0QY!)D'W
M&/\>TY+GX_'G$]R!<D$W$:`#AK<%T'L[&F``#E`NX4PVM%Y2$>`N.4HB2/<A
M(Q1A>/#8`-DCY65ON,(KW!$J&!(`70`!E@G5.(`=(9`I)%(AF=@T9%2_\\D?
MM[M:G!AJWJ$KM\L%01`#4G,WX820AI<`P`0"'6#*\7X+_,Q'L]T$%0YZ)<`O
M$".GX>'"=`+Q6-+<-^(6`1`&(F#NZ!ZBVKT!(:HWRKT$2-#E/G]\^O?TQ]?<
M$`>9]S+T=7.=VZD[?22F[MX!Z^%$CT`-+=\(294$-$&5>?#/<A`&:.#TS?T;
M7=K<<_(62+`$%N,3UID'(8I@H'0Y!V`&9@"ZVX,Y5R/_`!0(`3W.XS_>^!>C
M`-09%=9I`ADP57Z/:1EP.2P(3+S'*HOW$'J!*K*.N._A`#FPX',I!77Y%%8>
M%5,16%2#`WF3!U(0HJOTH1LTIF<J2!T@QVX0H'SDM@B9/Y5?_'E3_'W_H?B#
M:=J]!;F/\O!-3@>A(/`K"%Y<]N_E`*JT[C6V05?Z_=VO03:-.Q?D_65:$@[@
M`!W0>K>0FSD@_GR4._)_0?)?_UO4/>++@N</WV(`""`?-0@(?X>(B8J+C(V.
MCXE)?R-Q1`X&&AH)$UN=$QM;FPFC$Q.;9CDW-P8$!`X@%R<?AG]1?PA)(PR+
M-A<@!`8&.</$9IH)F<0YP<RM_PY$0"=3A@A1"`Q#-K20W-W>O`PUB$E`%Y8.
MK>D.KVYN'41$%T!`;0SV?X2'A.(^(TDVNQ`AJ+$+H`\&"#[$V0'D0X]R%R)&
M;#@H29P_#$:,2U+H5IQ9169]&TF26P]$-B0A*'(H29MM+27=^G"H8XU\26B*
MFU03@;9;A7`QJ+<SGZ.!^@RUV<@B%PM<&&&6G$IU&T>@CSK>DME1JU9%A:[V
MK'EK[%%:715Q]$FUK=NW<./*G4NWKMV[>//JW<NW;Z*P@/'54(GKVEJ5'#F.
M@+KV;]"P`0VY3)*+6N&6&@]+KDD909Q='=O4:]GS<N&,`R^O!7R-@5C.FZ^1
M31WU4?^-'4]Q]_B,X.F4#RP4[EA(<PB+.$,^^,C)0.'./TF&#&FS,,F)P0P^
MYK:Q,`Z-.">H)-FQP]_P$RS(GV"0<L>4])^'L.S^<<>0['%\!.?^@3R+,52P
M<,(.P.W0QE,#$C3"3X?$,08+#;$0Q4(U##%%#2,0V%DCUXPP2W-02'"%1HL9
MZ%H<(RQXP0!7L#"$AT5<LT]`T-D`4!PIL<"=)!]H=$$:8OCP1@I7#&?##@=]
MD-T0<5PA@1TCL&!/'$F$D^$N"\;QPAL9^A`'BA^T<=\'3(Y7`WP[#-8;`^\=
MA%$D35H@!@)CW,3`<1ARMX-4B1!$11H.,`"$!4J(P<"*@?[_DX0#:0"!P``P
M_'#!%`PXX$:&8HBA9")45DH`$.#E)(8#?]A@1Q9:?%`'&6Y\<($8;MB#`*,.
MU""&$G7\X4,4.[SJ0)4^[+#.218\84\':72`C9(.B$%#1G^`(,8%.[DA!A`,
MX.9&&A=HE$BE%$!1I;4T+,B`M<K2R,@`8`"`A05N:`&`&"E\X2X9#(@A+Q8D
MG+H"`&\(00(6'`R@!Q98Z"$&(ME>\82[5:20!@?V8I&%&V"LP,,+6I`AQAON
M,O'&%$(``(`2=SA`,#YQV+&'R74X`"D6`'`@A@6Y2J`$%DJ\X<8=%-!A\0"J
MNDM!"DF<H83)1.I\<@HT8921&&"D_R$$&%5@`0,45U@`\0L7-2+&RW=HP<,=
M7D-!AQ(2<,###T]@H872=4BP`@D#4+#"$W:0P(,%%O#``0+F7/&!$(+?L;8=
M/,A]QPI:!%XH$WJ\P0,89X"QQP!?Z*$X``.L/$(/;G/P!!,OP'`V!TQ(L$<5
M/F#QQ1U,8/'#%RN<$?<30JS``:$PI```&$)4L?'29WQA`:D)V?!'&BNX#'G@
M6KRP@A[%;Z[14XI8S@,%%/"0Q1T`D-$X!5_P\`083,@#Q0!0`"!$&^`[T`8`
M>D0$`P!7@,%#%:>"P0"`\`8L2```3Y#''K#P`B7H(0ETT(,%5B"&'HC!#@[0
M@Q)JQP,HB/^N#0>D6:0(!@0W0(%J2KC"OR@``!X4CPE`&$`$V3>`%=EA@@"@
M@!)6D`(]\.!DK"K$#GJ0!.BE``8I=$#-LH"%5L'/#4Z12AE.=H8[?$$(A)(`
M%BA`!@M400)(',#-)!`_"UR``B0`PA^40($!R%`)'Y"`%H0@!@[0(05BN`,6
M"KBY6RFA@7NX@`/)P$,Q2,`"UM,#&8SG00[\(0X7>,,3+`"#%1`*#&*`0O7`
MH(03K``&0M`#&,I0A2_\089ZT`,`4C``+)H/>W:\X1/DI00[B/$C23``#TE@
M2C?4S&QBQ.(`,/@!F2#B`O+*`A)3<`8ZI$&5=0`#'5J9PP6208;_3$@!";(`
MA"180'84P`(9HH`=!J3@?R\C`11X<#F]O<`.M4L!&+*0@MKMCP3GU`,'L.!"
M7/TA(G4```E4]X;`<5()/^#E'^S%`27LP0X4@,$I*<`!QK&18&FH`AT:^M`O
M*.%A1_M"%FR$@#3PP`YZV$.T/NI!)8"!7U!`W4D6080GT($"+SC!`-YPA3HR
M@0(:8``5?J!15D5R#V\H`](NX(;B54$(;J#!>]I@@R&\@0)5X(`#[)!#&+0.
M`4[:PPM>D`(3(K%@(Y!`%<"@!2U(@(Q_`(Z^Z$"',[C!`8H#PQN`4(8W_`$*
M)(@@UU[P@R2XX0=(>P%6M4"$$:1@#W0@B`$!IE`&)`I0#)%-#@.N0`80I.`%
M(R!@"BY@!_8]`59:@$+4&'$5]B1BM2U!B/.V@@B68(5&E-$,`P9`@C=\YBG.
M2TA0;O$21!0S)H>(S'$[XIKDCN.X-0DN+9J+$M@*]Y^L5$1`7&-,J/AE*B,P
<H0-\P);OVF4PI3*F>>MRC[CR:;UP84U;`@$`.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
